https://openbell.ai/ 2026-11-07T20:41:01.585Z hourly 1.0 https://openbell.ai/support 2026-11-07T20:41:01.585Z monthly 0.7 https://openbell.ai/privacy 2026-11-07T20:41:01.585Z monthly 0.5 https://openbell.ai/terms 2026-11-07T20:41:01.585Z monthly 0.5 https://openbell.ai/feed.json 2026-11-07T20:41:01.585Z hourly 0.8 https://openbell.ai/news/BMPS:1794081745000 2026-11-07T20:02:25.000Z daily 0.9 https://cdn.brandfetch.io/BMPS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Banca Monte dei Paschi di Siena Reports Q3 2026 Financial Results Banca Monte dei Paschi di Siena reported Q3 2026 net profit of €543 million, up 14.6% year over year and above market expectations. The bank raised its full-year pre-tax profit forecast to more than €3.7 billion from €3.6 billion. For the first nine months, total funding was €300 billion and gross wealth inflows were €18 billion; gross non-performing loans were €3.7 billion, or 2.4% of total loans, and the CET1 ratio rose to 16.4%. https://openbell.ai/news/AF:1794081736000 2026-11-07T20:02:16.000Z daily 0.9 https://cdn.brandfetch.io/AF/w/400/h/400?c=1idopYfmtR7ZKg8QMud KLM Announces Major Restructuring and Workforce Reduction KLM announced a restructuring targeting an additional €1 billion in annual earnings improvement, raising its total target to €1.4 billion. The plan includes cutting its workforce by 15% and reorganizing or transferring about 5,000 positions, including outsourcing some ground services and customer contact center operations and moving 2,000 roles to the wider Air France-KLM group. CEO Marjan Rintel cited global instability, high fuel prices and industry pressures as reasons for the changes. https://openbell.ai/news/NVS:1794081691000 2026-11-07T20:01:31.000Z daily 0.9 https://cdn.brandfetch.io/NVS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Novartis Discontinues Development of Pelacarsen for Atherosclerotic Cardiovascular Disease Novartis will discontinue development of pelacarsen for atherosclerotic cardiovascular disease after the therapy failed to meet the primary endpoints in the Phase 3 Lp(a)HORIZON trial. The company will continue studying pelacarsen for calcific aortic valve stenosis; the drug was originally discovered by Ionis Pharmaceuticals. https://openbell.ai/news/GOVX:1794060318000 2026-11-07T14:05:18.000Z daily 0.9 https://cdn.brandfetch.io/GOVX/w/400/h/400?c=1idopYfmtR7ZKg8QMud GeoVax Labs Terminates CEO David A. Dodd for Cause GeoVax Labs terminated David A. Dodd as president and CEO effective immediately, citing his refusal to comply with Board-approved directives. Dodd remains a director and Board chairman. The company said it does not intend to provide severance or full option vesting, though the determination of cause may be subject to legal or arbitration review. https://openbell.ai/news/KPTI:1794060308000 2026-11-07T14:05:08.000Z daily 0.9 https://cdn.brandfetch.io/KPTI/w/400/h/400?c=1idopYfmtR7ZKg8QMud Karyopharm Therapeutics Receives Nasdaq Delisting Notice Following Chapter 11 Filing Nasdaq notified Karyopharm Therapeutics on November 4, 2026, that it would delist the company’s securities following its Chapter 11 filing; Karyopharm will not appeal. Trading is scheduled to be suspended at the market open on November 11, after which the shares are expected to trade over the counter as KPTIQ. The bankruptcy plan provides for no distribution to common or preferred stockholders, and the company expects its existing equity securities to have no value. https://openbell.ai/news/CELZ:1794060299000 2026-11-07T14:04:59.000Z daily 0.9 https://cdn.brandfetch.io/CELZ/w/400/h/400?c=1idopYfmtR7ZKg8QMud Creative Medical Technology Holdings Reports 3Q 2026 Financial Results Creative Medical Technology Holdings reported no revenue in the third quarter of 2026, unchanged from a year earlier. Its net loss widened as research and development expenses rose 244% to $1.6 million, including $1.17 million in stock-based expenses tied to its BioDefense investment and higher development costs across other platforms; lower ADAPT trial expenses partly offset the increase. General and administrative expenses climbed 43% to $1.1 million, driven by higher compensation and legal fees. https://openbell.ai/news/ELEF:1794060295000 2026-11-07T14:04:55.000Z daily 0.9 https://cdn.brandfetch.io/ELEF/w/400/h/400?c=1idopYfmtR7ZKg8QMud Silver Elephant Mining Wins Ruling Reversing Pulacayo-Paca Contract Cancellation Bolivia’s Supreme Tribunal of Justice ruled in favor of Silver Elephant Mining subsidiary Apogee Minerals Bolivia, annulling COMIBOL’s December 16, 2024 cancellation of the Pulacayo-Paca Mining Production Contract. Signed in 2019, the contract grants exclusive rights to develop and mine the silver project for up to 30 years. Silver Elephant was notified of the decision on November 5, 2026; implementation by Bolivian authorities remains pending. https://openbell.ai/news/MERC:1794060287000 2026-11-07T14:04:47.000Z daily 0.9 https://cdn.brandfetch.io/MERC/w/400/h/400?c=1idopYfmtR7ZKg8QMud Mercer International Inc. Reports Third Quarter 2026 Financial Results Mercer International reported third-quarter 2026 Operating EBITDA of negative $2.9 million, improved from negative $28.1 million a year earlier, while its net loss narrowed to $59.2 million, or $0.88 per share, from $80.8 million, or $1.21 per share. The company said its “One Goal One Hundred” program generated $22.0 million in quarterly cost savings. It also cited a previously announced restructuring support agreement involving $1.275 billion in senior notes and $400 million in new capital to strengthen its balance sheet. Pulp results benefited from Peace River mill government grants and higher energy sales realizations, partly offset by planned maintenance and fiber costs. https://openbell.ai/news/INM:1794060284000 2026-11-07T14:04:44.000Z daily 0.9 https://cdn.brandfetch.io/INM/w/400/h/400?c=1idopYfmtR7ZKg8QMud InMed Pharmaceuticals Completes Merger with Mentari Therapeutics InMed Pharmaceuticals completed its merger with privately held Mentari Therapeutics, and the combined company will operate as Mentari Therapeutics, Inc. The company also completed its redomestication from British Columbia to Nevada. Before the merger, Mentari completed private financings totaling approximately $490 million in gross proceeds, including the conversion of $50 million in convertible notes plus accrued interest. The combined company’s shares are expected to begin trading on the Nasdaq Capital Market under ticker MTRI on November 9, 2026. https://openbell.ai/news/XHLD:1794060283000 2026-11-07T14:04:43.000Z daily 0.9 https://cdn.brandfetch.io/XHLD/w/400/h/400?c=1idopYfmtR7ZKg8QMud TEN Holdings Reports Third Quarter 2026 Financial Results TEN Holdings reported third-quarter 2026 revenue of $640,000, up 17.9% year over year, and a net loss of $3.734 million. The loss included a $1.8 million write-off of previously capitalized service contracts and about $500,000 in legal expenses. The company is transitioning from managed services to a recurring subscription-based SaaS model through its TEN Digital Experience Platform, with plans to expand AI, automation, and advanced analytics capabilities. TEN Holdings also adjourned its 2026 Annual Meeting of Stockholders.